A panel of vaccine experts at the Centers for Disease Control and Prevention voted unanimously to recommend the two mRNA vaccines over the Johnson & Johnson vaccine due to concerns about a rare but severe blood clotting condition.

"I just have a real problem with a recommendation for anyone to get a vaccine that 1 per 100,000 women ages 30 to 49 years old will have a condition with a case fatality rate of 15%," said Pablo Sanchez, a member of the CDC’s Advisory Committee on Immunization Practices and a professor of pediatrics at Ohio State University.

​​DOCTORS CAUTION CDC AGAINST CHANGING 'FULLY VACCINATED' STANDARD FOR NOW

Members of the Advisory Committee on Immunization Practices cited nine deaths due to thrombosis with thrombocytopenia out of the roughly 17.2 million doses administered since the vaccine was authorized for use in adults in February. Seven women and two men, ranging in age from 28 to 62, died after getting the shot. CDC Director Rochelle Walensky will decide whether to adopt the panel’s recommendation as agency policy later Thursday.

CLICK HERE TO READ MORE FROM THE WASHINGTON EXAMINER

The J&J vaccine, which consists of just one shot compared to two shots with the mRNA vaccines, has been bedeviled by links to thrombosis with thrombocytopenia syndrome since the rollout last spring. The Food and Drug Administration and the CDC recommended a 10-day pause on all vaccine administrations in April after six women between the ages of 18 to 48 developed a blood clot within six to 13 days of receiving the shot.